NEWS RELEASE
Biosensors’ AxxionTM DES Shows Positive Results in
European Study
Singapore, 28 February 2006 - Biosensors International Group, Ltd. (“Biosensors” or
the “Company”, Bloomberg: BIG SP), a developer, manufacturer and marketer of
innovative medical devices for interventional cardiology and critical care procedures,
today announced that its EAGLE study involving its AxxionTM drug-eluting stent (“DES”)
achieved the primary endpoint set for the study, and that the data showed 0% MACE at
30 days.
MACE is a measure of the percentage of patients in the study who died, suffered a heart
attack or needed repeat procedure(s) post DES implantation.
The European Study of AxxionTM and Glycocalix Long-term Evaluation, also known as
“EAGLE”, is a 6-9 month randomized, multi-centre safety and efficacy study conducted
in Germany and designed to compare the clinical outcomes in patients receiving the
AxxionTM DES and Calix stents. The primary endpoint was 30-day MACE and
secondary endpoints are angina status and MACE at 6 months and angiography and
quantitative coronary angiography at 6 and 9 months.
The results of this study were presented in a scientific symposium organised in
conjunction with the Singapore LIVE 2006 convention, by Prof. Thomas Ischinger of
Munich-Bogenhausen State Hospital, Germany in a well-attended function room at
Suntec City last evening. The Singapore LIVE 2006 convention is an annual event
organized by the Singapore National Heart Centre and is attended by international
cardiologists including leading cardiologists from Asia and Europe
.
Biosensors’ Chief Technology Officer, Mr. John Shulze, commented: “We are very
pleased with the strong clinical performance of AxxionTM particularly with respect to its
30-day MACE. We will continue to study the results of patients to determine the
secondary endpoints that include safety and efficacy in a longer time frame. For now, we
will continue to focus on enhancing our current distribution network for AxxionTM and
continue with our sales momentum.”
AxxionTM became Biosensors’ first DES for coronary artery disease to be launched within
the European Union after receiving a CE Mark in July 2005.
##End of Release##
Media Contact
Biosensors International Group
Ms Tina Lim, Executive, Corporate Communications
Tel
: (65) 6213 5712
Email : media@biosensors.com
Media Relations / Investor Relations Firm
United States
Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com
About Biosensors International Group, Ltd.
Biosensors develops, manufactures and markets innovative medical devices used in
interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as
a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from
traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has
internally developed technology to address each component of a drug-eluting stent system,
including a stent, a stent delivery catheter, a bioresorbable polymer and a proprietary antirestenotic drug. It is pursuing two separate drug-eluting stent programs, BioMatrix™ and
TM
Axxion , and has licensed aspects of its drug-eluting stent technology to four companies.
Forward Looking Statements
Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking
terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the
negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but
not limited to, customer acceptance and market share gains, competition from companies that have greater financial
resources; introduction of new products into the marketplace by competitors; successful product development;
dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and
economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by,
the forward-looking statements. The forward-looking statements speak only as of the date of this release and
Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
Sponsorship statement: Citigroup Global Markets Singapore Pte. Ltd. was the Sole Global Co-ordinator and Sole
Bookrunner, Joint Lead Manager and Underwriter of the offering (the “Offering”) in respect of 185,434,000 shares of
the Company pursuant to the prospectus issued by the Company dated 22 April 2005. The Joint Lead Manager and
Underwriter of the Offering was UBS AG, acting through its business group UBS Investment Bank. The Joint Lead
Manager, Local Coordinator and Underwriter for the Offering was UOB Asia Limited.